WO2011147951A8 - Cycloamino derivatives as gpr119 agonists - Google Patents

Cycloamino derivatives as gpr119 agonists Download PDF

Info

Publication number
WO2011147951A8
WO2011147951A8 PCT/EP2011/058703 EP2011058703W WO2011147951A8 WO 2011147951 A8 WO2011147951 A8 WO 2011147951A8 EP 2011058703 W EP2011058703 W EP 2011058703W WO 2011147951 A8 WO2011147951 A8 WO 2011147951A8
Authority
WO
WIPO (PCT)
Prior art keywords
gpr119 agonists
compounds
cycloamino
derivatives
cycloamino derivatives
Prior art date
Application number
PCT/EP2011/058703
Other languages
French (fr)
Other versions
WO2011147951A1 (en
Inventor
Oscar Barba
James Charles Bell
Tom Banksia Dupree
Peter Timothy Fry
Lisa Sarah Bertram
Matthew Colin Thor Fyfe
William Gattrell
Revathy Perpetua Jeevaratnam
John Keily
Thomas Martin Krulle
Russell Walker Mcdonald
Trevor Morgan
Chrystelle Marie Rasamison
Karen Lesley Schofield
Alan John William Stewart
Simon Andrew Swain
David Matthew Withall
Original Assignee
Prosidion Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1008985.2A external-priority patent/GB201008985D0/en
Priority claimed from GBGB1019547.7A external-priority patent/GB201019547D0/en
Priority claimed from GB1103283.6A external-priority patent/GB2488360A/en
Application filed by Prosidion Limited filed Critical Prosidion Limited
Publication of WO2011147951A1 publication Critical patent/WO2011147951A1/en
Publication of WO2011147951A8 publication Critical patent/WO2011147951A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.
PCT/EP2011/058703 2010-05-28 2011-05-27 Cycloamino derivatives as gpr119 antagonists WO2011147951A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1008985.2A GB201008985D0 (en) 2010-05-28 2010-05-28 Novel compounds
GB1008985.2 2010-05-28
GB1019547.7 2010-11-19
GBGB1019547.7A GB201019547D0 (en) 2010-11-19 2010-11-19 Novel compounds
GB1103283.6A GB2488360A (en) 2011-02-25 2011-02-25 Heterocyclic GPCR agonists
GB1103283.6 2011-02-25

Publications (2)

Publication Number Publication Date
WO2011147951A1 WO2011147951A1 (en) 2011-12-01
WO2011147951A8 true WO2011147951A8 (en) 2012-03-15

Family

ID=44227954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/058703 WO2011147951A1 (en) 2010-05-28 2011-05-27 Cycloamino derivatives as gpr119 antagonists

Country Status (3)

Country Link
AR (1) AR081252A1 (en)
TW (1) TW201209054A (en)
WO (1) WO2011147951A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031618B1 (en) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Compounds as modulators of gpr-119
WO2013169531A1 (en) 2012-05-09 2013-11-14 Boehringer Ingelheim International Gmbh Methods for making oxetan-3-ylmethanamines
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2016116900A1 (en) 2015-01-23 2016-07-28 Gvk Biosciences Private Limited Inhibitors of trka kinase
WO2016131198A1 (en) * 2015-02-18 2016-08-25 Eli Lilly And Company Pyrazole compounds
CN104788386A (en) * 2015-04-24 2015-07-22 湖南华腾制药有限公司 Preparation method of fluorine-containing pyrimidine compound
MA51738A (en) 2018-02-05 2021-05-12 Alkermes Inc COMPOUNDS FOR THE TREATMENT OF PAIN
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
BR112022023359A2 (en) 2020-05-19 2023-04-18 Kallyope Inc AMPK ACTIVATORS
CN116390925A (en) 2020-06-26 2023-07-04 卡尔优普公司 AMPK activator

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
JP4958560B2 (en) 2003-12-24 2012-06-20 プロシディオン・リミテッド Heterocyclic derivatives as GPCR receptor agonists
US20080086006A1 (en) 2004-12-22 2008-04-10 Nelson Todd D Process for Making Substituted Piperidines
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
NZ556017A (en) 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
EP2308840A1 (en) 2005-06-30 2011-04-13 Prosidion Limited GPCR agonists
JP2008545010A (en) 2005-06-30 2008-12-11 プロシディオン・リミテッド G protein-coupled receptor agonist
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP2013201B1 (en) 2006-04-06 2012-07-25 Prosidion Limited Heterocyclic gpcr agonists
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
EP2059516A1 (en) * 2006-08-30 2009-05-20 BIOVITRUM AB (publ) Pyridine compounds for treating gpr119 related disorders
TWI387585B (en) 2006-09-01 2013-03-01 Dow Agrosciences Llc Insecticidal n-substituted (heteroaryl)alkyl sulfilimines
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
KR20090097184A (en) 2006-12-06 2009-09-15 스미스클라인 비참 코포레이션 Chemical compounds and uses
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
EP2114936A1 (en) 2007-01-04 2009-11-11 Prosidion Limited Piperidine gpcr agonists
CL2008000018A1 (en) 2007-01-04 2008-08-01 Prosidion Ltd COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE
EP2114933B1 (en) 2007-01-04 2011-09-07 Prosidion Ltd Piperidine gpcr agonists
CL2008000017A1 (en) 2007-01-04 2008-08-01 Prosidion Ltd COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE
JP2010539152A (en) 2007-09-10 2010-12-16 プロシディオン・リミテッド Compounds for the treatment of metabolic disorders
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CA2719507C (en) 2008-03-31 2018-03-27 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
CA2728042A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Piperidinyl gpcr agonists
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812642D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
ATE557024T1 (en) 2008-07-10 2012-05-15 Prosidion Ltd PIPERIDINE COMPOUNDS AS GPCR AGONISTS
JP5657518B2 (en) 2009-02-18 2015-01-21 武田薬品工業株式会社 Fused heterocyclic compounds

Also Published As

Publication number Publication date
WO2011147951A1 (en) 2011-12-01
TW201209054A (en) 2012-03-01
AR081252A1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
WO2011147951A8 (en) Cycloamino derivatives as gpr119 agonists
WO2012117000A8 (en) 3-amino-pyridines as gpbar1 agonists
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2009079008A8 (en) Benzopyrans and analogs as rho kinase inhibitors
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MX2010002312A (en) Triazolopyridine compounds and their use as ask inhibitors.
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
TW201000488A (en) Heterocyclic derivatives
WO2012149157A3 (en) Heterocyclic compounds for the inhibition of pask
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
TN2012000248A1 (en) Novel spiropiperidine compounds
EP2881384A8 (en) Partially saturated nitrogen-containing heterocyclic compound
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
IN2012DN03182A (en)
IL230635A (en) 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2013041519A9 (en) Ror gamma modulators
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
UA99787C2 (en) Lactams as beta secretase inhibitors
WO2008131946A3 (en) Substituted amide derivatives
WO2011006935A3 (en) Tetrazole derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11725017

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11725017

Country of ref document: EP

Kind code of ref document: A1